Stock NTLA INTELLIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
21.98 USD +5.88% Intraday chart for Intellia Therapeutics, Inc. +0.69% -27.91%
Apr. 15 Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer CI
Mar. 25 Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
CI
North American Morning Briefing : Traders Await -2-
DJ
Intellia Therapeutics Q4 Loss Widens
MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis
MT
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
CI
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
CI
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy
MT
Intellia Therapeutics Shares Fall After Net Loss Narrows, but Revenue Falls in Q3
MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting
CI
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
CI
Intellia Therapeutics, Regeneron Pharmaceuticals Broaden Research Collaboration to Neurological, Muscular Disease Therapies
MT
Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. Expands Research Collaboration to Develop Crispr-Based Therapies for the Treatment of Neurological and Muscular Diseases
CI
Intellia Therapeutics Shares Fall After Q2 Net Loss Widens, Revenue Drops
MT
Intellia Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema
CI
INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTLA Stock
  4. News Intellia Therapeutics, Inc.
  5. Highlights